Literature DB >> 29191471

Nerve-Sparing Approach Improves Outcomes of Patients Undergoing Minimally Invasive Radical Hysterectomy: A Systematic Review and Meta-Analysis.

Giorgio Bogani1, Diego Oreste Rossetti2, Antonino Ditto2, Mauro Signorelli2, Fabio Martinelli2, Lavinia Mosca2, Cono Scaffa2, Umberto Leone Roberti Maggiore2, Valentina Chiappa2, Ilaria Sabatucci2, Domenica Lorusso2, Francesco Raspagliesi2.   

Abstract

Few studies have investigated the efficacy and safety of the nerve-sparing approach via minimally invasive surgery for the treatment of cervical cancer. We aimed to review the current evidence comparing nerve-sparing minimally invasive radical hysterectomy (NS-MRH) with conventional minimally invasive radical hysterectomy (MRH). This systematic review was registered in the International Prospective Register of Systematic Reviews (CRD#57655). Overall, 675 patients were included: 350 (51.9%) and 325 (48.1%) patients undergoing MRH and NS-MRH, respectively. MRH was associated with a shorter operative time in comparison with NS-MRH (mean difference = 32.57 minutes; 95% CI, 22.87-42.48). The estimated blood loss (mean difference = 97.14 mL, 20.01-214.29) and transfusion rate (odds ratio [OR] = 0.67; 95% confidence interval [CI], 0.15-3.01) did not differ statistically between the 2 groups. The risk of developing intraoperative (OR = 0.43; 95% CI, 0.08-2.23) and severe postoperative (OR = 0.63; 95% CI, 0.17-2.39) complications was similar between NS-MRH and MRH. Patients undergoing NS-MRH experienced lower voiding (OR = 0.39; 95% CI, 0.19-0.81) dysfunction rates than patients undergoing MRH. Moreover, a trend toward lower sexual (OR = 0.25; 95% CI, 0.06-1.07) and rectal (OR = 0.12; 95% CI, 0.01-1.02) issues was observed for patients having NS-MRH compared with patients undergoing MRH. Survival outcomes are not influenced by the type of surgical approach (recurrence [OR = 1.27; 95% CI, 0.49-3.28] and death [OR = 1.01; 95% CI, 0.36-2.83]) rates. The pooled data suggested that NS-MRH is equivalent to MRH for the treatment of cervical cancer and may be superior in reducing pelvic floor dysfunction rates. However, because of the low level of evidence of the included studies, further randomized trials are warranted.
Copyright © 2017 American Association of Gynecologic Laparoscopists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Minimally invasive surgery; Nerve sparing; Radical hysterectomy

Mesh:

Year:  2017        PMID: 29191471     DOI: 10.1016/j.jmig.2017.11.014

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  4 in total

1.  Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery.

Authors:  Giorgio Bogani; Diego Rossetti; Antonino Ditto; Fabio Martinelli; Valentina Chiappa; Chiara Leone; Umberto Leone Roberti Maggiore; Domenica Lorusso; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2018-11-27       Impact factor: 4.401

2.  Total laparoscopic vs. conventional open abdominal nerve-sparing radical hysterectomy: clinical, surgical, oncological and functional outcomes in 301 patients with cervical cancer.

Authors:  Marcello Ceccaroni; Giovanni Roviglione; Mario Malzoni; Francesco Cosentino; Emanuela Spagnolo; Roberto Clarizia; Paolo Casadio; Renato Seracchioli; Fabio Ghezzi; Daniele Mautone; Francesco Bruni; Stefano Uccella
Journal:  J Gynecol Oncol       Date:  2020-11-27       Impact factor: 4.401

3.  Surgical, Urinary, and Survival Outcomes of Nerve-sparing Versus Traditional Radical Hysterectomy: A Retrospective Cohort Study in China.

Authors:  Lei Li; Shuiqing Ma; Xianjie Tan; Sen Zhong; Ming Wu
Journal:  Am J Clin Oncol       Date:  2019-10       Impact factor: 2.339

4.  Sexual, bladder and bowel function following different minimally invasive techniques of radical hysterectomy in patients with early-stage cervical cancer.

Authors:  K Baessler; S Windemut; V Chiantera; C Köhler; J Sehouli
Journal:  Clin Transl Oncol       Date:  2021-05-18       Impact factor: 3.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.